Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Cell Medica
Cell Medica
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Cell Medica appoints new CEO
Design & Build
Cell and Gene Therapy Catapult opens manufacturing centre
More than £60 million of UK government investment is being used to develop the new centre, which aims to accelerate growth of the industry in the UK
Recruitment
New CFO to lead Cell Medica financing
Research & Development
Cell Medica appoints CSO to accelerate R&D for CAR and TCR programmes
Media
Cell Medica acquires WT1 cancer immunotherapy from CGT Catapult
The acquisition transfers rights for WT1-TCR cell therapy from CGT Catapult to Cell Medica, also establishing development and manufacturing collaboration
Research & Development
Cell Medica and UCL to develop T cell receptor cancer products
Cell Medica gains an exclusive worldwide option and licensing agreement for these technologies
Pharmaceutical
Cell Medica begins commercial production at cell therapy facility in Germany
The first product has been manufactured and delivered to the patient
Subscribe now